Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia

Cancer Letters

Volumn 366, Issue 2, 2015, Pages 160-172

  Huang, Jingcao ^a,b   Lyu, Hui ^a   Wang, Jianxiang ^b   Liu, Bolin ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Acute myeloid leukemia; Chemotherapy; Survivin; Targeted therapy; YM155

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DOXORUBICIN; ETOPOSIDE; SEPANTRONIUM BROMIDE; SURVIVIN; BIRC5 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; NAPHTHOQUINONE;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG TARGETING; G2 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; GENE TARGETING; HL 60 CELL LINE; HUMAN; HUMAN CELL; KASUMI 1 CELL LINE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MYELOID LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SURVIVIN GENE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DOXORUBICIN; DRUG SYNERGISM; ETOPOSIDE; HL-60 CELLS; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; NAPHTHOQUINONES;

EID: 84937978202     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.05.033     Document Type: Article

References (50)

1. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 2008, 8:61-70.
2. Marusawa H., Matsuzawa S., Welsh K., Zou H., Armstrong R., Tamm I., et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 2003, 22:2729-2740.
3. Dohi T., Okada K., Xia F., Wilford C.E., Samuel T., Welsh K., et al. An IAP-IAP complex inhibits apoptosis. J. Biol. Chem 2004, 279:34087-34090.
4. Lens S.M., Vader G., Medema R.H. The case for Survivin as mitotic regulator. Curr. Opin. Cell Biol 2006, 18:616-622.
5. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-584.
6. Fukuda S., Pelus L.M. Survivin, a cancer target with an emerging role in normal adult tissues. Mol. Cancer Ther 2006, 5:1087-1098.
7. Coumar M.S., Tsai F.Y., Kanwar J.R., Sarvagalla S., Cheung C.H. Treat cancers by targeting survivin: just a dream or future reality?. Cancer Treat. Rev 2013, 39:802-811.
8. Kelly R.J., Lopez-Chavez A., Citrin D., Janik J.E., Morris J.C. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol. Cancer 2011, 10:35.
9. Zaffaroni N., Daidone M.G. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist. Updat 2002, 5:65-72.
10. Wang S., Huang X., Lee C.K., Liu B. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene 2010, 29:4225-4236.
11. Wang S., Huang J., Lyu H., Cai B., Yang X., Li F., et al. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. Breast Cancer Res 2013, 15:R101.
12. Fulda S. Inhibitor of apoptosis proteins in hematological malignancies. Leukemia 2009, 23:467-476.
13. Carter B.Z., Milella M., Altieri D.C., Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood 2001, 97:2784-2790.
14. Carter B.Z., Wang R.Y., Schober W.D., Milella M., Chism D., Andreeff M. Targeting Survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells. Cell Cycle 2003, 2:488-493.
15. Carter B.Z., Qiu Y., Huang X., Diao L., Zhang N., Coombes K.R., et al. Survivin is highly expressed in CD34+38- leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood 2012, 120:173-180.
16. Cheng Q., Ling X., Haller A., Nakahara T., Yamanaka K., Kita A., et al. Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int. J. Biochem. Mol. Biol 2012, 3:179-197.
17. Nakamura N., Yamauchi T., Hiramoto M., Yuri M., Naito M., Takeuchi M., et al. Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin. Mol. Cell. Proteomics 2012, 11:M111. 013243.
18. Yamauchi T., Nakamura N., Hiramoto M., Yuri M., Yokota H., Naitou M., et al. Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression. Biochem. Biophys. Res. Commun 2012, 425:711-716.
19. Giaccone G., Zatloukal P., Roubec J., Floor K., Musil J., Kuta M., et al. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J. Clin. Oncol 2009, 27:4481-4486.
20. Kelly R.J., Thomas A., Rajan A., Chun G., Lopez-Chavez A., Szabo E., et al. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol 2013, 24:2601-2606.
21. Tolcher A.W., Quinn D.I., Ferrari A., Ahmann F., Giaccone G., Drake T., et al. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann. Oncol 2012, 23:968-973.
22. Lewis K.D., Samlowski W., Ward J., Catlett J., Cranmer L., Kirkwood J., et al. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest. New Drugs 2011, 29:161-166.
23. Cheson B.D., Bartlett N.L., Vose J.M., Lopez-Hernandez A., Seiz A.L., Keating A.T., et al. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer 2012, 118:3128-3134.
24. Kita A., Mitsuoka K., Kaneko N., Nakata M., Yamanaka K., Jitsuoka M., et al. Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab. J. Pharmacol. Exp. Ther 2012, 343:178-183.
25. Chen J., Pise-Masison C.A., Shih J.H., Morris J.C., Janik J.E., Conlon K.C., et al. Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia. Blood 2013, 121:2029-2037.
26. Cai B., Lyu H., Huang J., Wang S., Lee C.K., Gao C., et al. Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response. Cancer Lett 2013, 335:343-350.
27. Huang J., Wang S., Lyu H., Cai B., Yang X., Wang J., et al. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells. Mol. Cancer 2013, 12:134.
28. Wang S., Huang J., Lyu H., Lee C.K., Tan J., Wang J., et al. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death Dis 2013, 4:e556.
29. Chou T.-C., Martin N. CompuSyn Software for Drug Combinations and for General Dose-Effect Analysis, and User's Guide ComboSyn, Inc., Paramus, NJ 2007. http://www.combosyn.com.
30. Cline M.S., Craft B., Swatloski T., Goldman M., Ma S., Haussler D., et al. Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser. Sci. Rep 2013, 3:2652.
31. Kanwar J.R., Kamalapuram S.K., Kanwar R.K. Survivin signaling in clinical oncology: a multifaceted dragon. Med. Res. Rev 2013, 33:765-789.
32. Ouchi M., Ouchi T. Distinct DNA damage determines differential phosphorylation of Chk2. Cancer Biol. Ther 2014, 15:1700-1704.
33. Nakahara T., Kita A., Yamanaka K., Mori M., Amino N., Takeuchi M., et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007, 67:8014-8021.
34. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010, 70:440-446.
35. Rauch A., Hennig D., Schafer C., Wirth M., Marx C., Heinzel T., et al. Survivin and YM155: how faithful is the liaison?. Biochim. Biophys. Acta 2014, 1845:202-220.
36. Fukuda S., Mantel C.R., Pelus L.M. Survivin regulates hematopoietic progenitor cell proliferation through p21WAF1/Cip1-dependent and -independent pathways. Blood 2004, 103:120-127.
37. Fukuda S., Pelus L.M. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 2001, 98:2091-2100.
38. Leung C.G., Xu Y., Mularski B., Liu H., Gurbuxani S., Crispino J.D. Requirements for survivin in terminal differentiation of erythroid cells and maintenance of hematopoietic stem and progenitor cells. J. Exp. Med 2007, 204:1603-1611.
39. Xing Z., Conway E.M., Kang C., Winoto A. Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J. Exp. Med 2004, 199:69-80.
40. Okada H., Bakal C., Shahinian A., Elia A., Wakeham A., Suh W.K., et al. Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J. Exp. Med 2004, 199:399-410.
41. Altznauer F., Martinelli S., Yousefi S., Thurig C., Schmid I., Conway E.M., et al. Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils. J. Exp. Med 2004, 199:1343-1354.
42. Zwerts F., Lupu F., De Vriese A., Pollefeyt S., Moons L., Altura R.A., et al. Lack of endothelial cell survivin causes embryonic defects in angiogenesis, cardiogenesis, and neural tube closure. Blood 2007, 109:4742-4752.
43. Gurbuxani S., Xu Y., Keerthivasan G., Wickrema A., Crispino J.D. Differential requirements for survivin in hematopoietic cell development. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:11480-11485.
44. Erba H.P., Sayar H., Juckett M., Lahn M., Andre V., Callies S., et al. Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Invest. New Drugs 2013, 31:1023-1034.
45. Smolewski P. Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs 2008, 11:204-214.
46. Zhu X., Ma Y., Liu D. Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. J. Hematol. Oncol 2010, 3:17.
47. NCCN National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-Acute Myeloid Leukemia 2014, NCCN Guidelines(NCCN.org) 2014.
48. Nakahara T., Kita A., Yamanaka K., Mori M., Amino N., Takeuchi M., et al. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci 2011, 102:614-621.
49. Glaros T.G., Stockwin L.H., Mullendore M.E., Smith B., Morrison B.L., Newton D.L. The "survivin suppressants" NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother. Pharmacol 2012, 70:207-212.
50. Arora R., Shuda M., Guastafierro A., Feng H., Toptan T., Tolstov Y., et al. Survivin is a therapeutic target in merkel cell carcinoma. Sci. Transl. Med 2012, 4:133ra156.